
Study Results Indicate Precision Therapies Make Up Approximately Half of FDA-Approved Oncology Drugs
This finding underlines the need for methods that address multiple genomic alterations and targeted therapies effective in tumors driven by variations in suppressor genes or transcription factors.





























